Clinical trial
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
NCT00488592 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00488592 |
|---|---|
| Title | Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers |
| Official title | Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) |
| Intervention type | Biological, Drug |
| Interventions | WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim), Montanide adjuvant |
| Enrollment | 10 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Jun 20, 2007 |
| Last update posted | Jul 12, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: